Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Insider Shannon Kelley Sells 1,077 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Shannon Kelley sold 1,077 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $400.00, for a total transaction of $430,800.00. Following the completion of the sale, the general counsel directly owned 10,397 shares of the company’s stock, valued at $4,158,800. This represents a 9.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $399.63 on Friday. Madrigal Pharmaceuticals, Inc. has a 12-month low of $353.54 and a 12-month high of $615.00. The company’s 50 day moving average price is $486.74 and its two-hundred day moving average price is $497.41. The firm has a market cap of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. The company has a quick ratio of 2.94, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period in the previous year, the business earned ($5.08) earnings per share. Equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Institutional Trading of Madrigal Pharmaceuticals

Large investors have recently made changes to their positions in the company. William Blair Investment Management LLC raised its position in Madrigal Pharmaceuticals by 4.0% during the third quarter. William Blair Investment Management LLC now owns 337,035 shares of the biopharmaceutical company’s stock valued at $169,852,000 after purchasing an additional 12,912 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Madrigal Pharmaceuticals by 2.5% during the third quarter. Russell Investments Group Ltd. now owns 50,545 shares of the biopharmaceutical company’s stock worth $25,473,000 after purchasing an additional 1,251 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Madrigal Pharmaceuticals by 3.5% in the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 28 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of Madrigal Pharmaceuticals by 17.3% in the 3rd quarter. Maryland State Retirement & Pension System now owns 1,098 shares of the biopharmaceutical company’s stock valued at $553,000 after purchasing an additional 162 shares in the last quarter. Finally, Ritholtz Wealth Management bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at $200,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Trending Headlines about Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Analysts Set New Price Targets

Several brokerages have weighed in on MDGL. Truist Financial reaffirmed a “buy” rating and issued a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Canaccord Genuity Group increased their target price on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group restated a “buy” rating and issued a $735.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group assumed coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $706.87.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.